Kymera Therapeutics (KYMR) Misses Q2 EPS by 8c

Kymera Therapeutics (NASDAQ: KYMR) reported Q2 EPS of ($0.78), $0.08 worse than the analyst estimate of ($0.70). Revenue for the quarter came in at $11.51 million versus the consensus estimate of $13.84 million.

For earnings history and earnings-related data on Kymera Therapeutics (KYMR) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Hertz cuts guidance, announces notes and stock offerings, shares sink
• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance